| Schedule of basic and diluted earnings per share, impact of two-class method |
The following table summarizes the impact of the two-class method: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended
September 30, | | Nine months ended
September 30, | | (in millions, except per share data) | | 2025 | | 2024 | | 2025 | | 2024 | | Basic EPS | | | | | | | | | | Net earnings attributable to AbbVie Inc. | | $ | 186 | | | $ | 1,561 | | | $ | 2,410 | | | $ | 4,300 | | | Earnings allocated to participating securities | | 10 | | | 10 | | | 30 | | | 30 | | | Earnings available to common shareholders | | $ | 176 | | | $ | 1,551 | | | $ | 2,380 | | | $ | 4,270 | | | Weighted-average basic shares outstanding | | 1,769 | | | 1,769 | | | 1,769 | | | 1,769 | | | Basic earnings per share attributable to AbbVie Inc. | | $ | 0.10 | | | $ | 0.88 | | | $ | 1.35 | | | $ | 2.41 | | | | | | | | | | | | Diluted EPS | | | | | | | | | | Net earnings attributable to AbbVie Inc. | | $ | 186 | | | $ | 1,561 | | | $ | 2,410 | | | $ | 4,300 | | | Earnings allocated to participating securities | | 10 | | | 10 | | | 30 | | | 30 | | | Earnings available to common shareholders | | $ | 176 | | | $ | 1,551 | | | $ | 2,380 | | | $ | 4,270 | | | Weighted-average shares of common stock outstanding | | 1,769 | | | 1,769 | | | 1,769 | | | 1,769 | | | Effect of dilutive securities | | 3 | | | 3 | | | 3 | | | 3 | | | Weighted-average diluted shares outstanding | | 1,772 | | | 1,772 | | | 1,772 | | | 1,772 | | | Diluted earnings per share attributable to AbbVie Inc. | | $ | 0.10 | | | $ | 0.88 | | | $ | 1.34 | | | $ | 2.41 | |
|